ClinicalTrials.gg
CompletedNCT06024408Updated Jul 31, 2025

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

A Phase 1 interventional study of ALN-PNP and Placebo in Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) and Genetic Risk Factor, sponsored by Regeneron Pharmaceuticals. Completed at 5 sites in South Korea. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Non-alcoholic Fatty Liver Disease with a site in Korea, Republic of — 7 open to participants now, 11 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Korea, Republic of.

Enrollment
53rd of 53
9 · median 145
Started
2024
with 6 others
Phase 1
4 of 61
1 open now
Registered
48th of 61
by date
Lead sponsor
3 of 61
Regeneron Pharmaceuticals

Among the 61 studies in Non-alcoholic Fatty Liver Disease with a site in Korea, Republic of, this one is the 53rd largest by enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2024, is one of 4 in phase 1, and was the 48th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

7 of the 61 studies in Non-alcoholic Fatty Liver Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Non-alcoholic Fatty Liver Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is researching an experimental drug called ALN-PNP. This study is focused on participants who are known to have nonalcoholic fatty liver disease (NAFLD), and a specific variant of the patatin-like phospholipase domain containing 3 (PNPLA3) gene.

The aim of this study is to see how safe, tolerable, and effective the study drug is.

This study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How the study drug works to change liver fat content in NAFLD
  • How much study drug and study drug metabolites (byproduct of the body breaking down the study drug) are in your blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
  • Better understanding of the study drug and NAFLD
03

Conditions studied

  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)
  • Genetic Risk Factor

Keywords

  • Homozygous
  • Heterozygous
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants from 18 (or country's legal age of adulthood) to 65 years of age, inclusive, at screening visit 1
  2. (BMI) from 23.0 kg/m\^2 to 40.0 kg/m\^2, inclusive, for East Asians (including but not limited to South Koreans, Chinese, Taiwanese, and Japanese) and BMI from 27.0 kg/m\^2 to 40.0 kg/m\^2, inclusive, for any other ethnicity at screening visit 1
  3. Meets genotype criteria for the rs738409:G PNPLA3 risk allele: homozygotes (for Part A and Part B) or heterozygotes (optional Part C); p.I148M variant (PNPLA3 rs738409:G [p.I148M]) at screening visit 1
  4. Liver fat content ≥8.5% as measured by MRI-PDFF at screening visit 3
  5. Generally stable diet (based on participant's recall) for at least 3 months prior to the screening visit

Key Exclusion Criteria:

  1. Evidence of other forms of known chronic liver disease, as defined in the protocol
  2. Has a to MRI examinations, such as persons with cardiac pacemaker and implants made out of metal (for example, cochlear implant, nerve stimulators, magnetic vascular clips, and metallic heart valve), severe claustrophobia, or other contraindications for MRI
  3. Is taking a medication to treat a co-morbid condition that is not permitted during the study
  4. Has any laboratory parameter assessments at screening, as defined in the protocol
  5. History of Type 1 diabetes
  6. Bariatric surgery within approximately 5 years prior or planned during the study period
  7. Has lost or gained more than 4.0% body weight over the 3 months prior to or during the screening period
  8. Has known (HIV) infection, evidence of current or chronic virus (HBV) infection, or current or chronic virus (HCV) infection, as defined in the protocol
  9. Was hospitalized (ie, >24 hours) for any reason within 30 days of the screening visit

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
9 participants (actual)

Study arms

  • Placebo comparator
    Part A: Placebo

    Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1

    Drug: Placebo

  • Experimental
    Part A: Low Dose

    Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1

    Drug: ALN-PNP

  • Experimental
    Part A: Mid Dose

    Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1

    Drug: ALN-PNP

  • Experimental
    Part A: High Dose

    Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1

    Drug: ALN-PNP

  • Placebo comparator
    Part B: Placebo

    Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1

    Drug: Placebo

  • Experimental
    Part B : Low Dose

    Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1

    Drug: ALN-PNP

  • Experimental
    Part B: Mid Dose

    Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1

    Drug: ALN-PNP

  • Experimental
    Part B: High Dose

    Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1

    Drug: ALN-PNP

  • Placebo comparator
    Part C: Placebo (Optional)

    Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1

    Drug: Placebo

  • Experimental
    Part C: High Dose (Optional)

    Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1

    Drug: ALN-PNP

Interventions

  • DrugALN-PNP

    Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

  • DrugPlacebo

    Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 253 days

  2. Severity of TEAEs

    Time frame: Up to 253 days

Secondary outcomes

  1. Change in liver fat fraction by magnetic resonance imaging proton density fat fraction (MRI-PDFF) in participants with NAFLD

    Time frame: Baseline up to 253 days

  2. Change in low-density lipoprotein cholesterol (LDL-C) in participants with NAFLD

    Time frame: Baseline up to 253 days

  3. Change in high-density lipoprotein cholesterol (HDL-C) in participants with NAFLD

    Time frame: Baseline up to 253 days

  4. Change in triglycerides (TG) in participants with NAFLD

    Time frame: Baseline up to 253 days

  5. Change in lipoprotein a (Lp(a)) in participants with NAFLD

    Time frame: Baseline up to 253 days

  6. Change in apolipoprotein A1 (ApoA1) in participants with NAFLD

    Time frame: Baseline up to 253 days

  7. Change in apolipoprotein B (ApoB) in participants with NAFLD

    Time frame: Baseline up to 253 days

  8. Concentration of ALN-PNP and potential major metabolite(s) in plasma over time

    Time frame: Up to 253 days

  9. Incidence of anti-drug antibodies (ADAs) to ALN-PNP

    Time frame: Up to 253 days

  10. Titer of anti-drug antibodies (ADAs) to ALN-PNP

    Time frame: Up to 253 days

07

Study locations

5 sites
  • Chungbuk National University Hospital
    Cheongju-si, Chungcheong Buk-do 28644, South Korea
  • CHA Bundang Medical Center
    Seongnam-si, Gyeonggi-do 13496, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Jul 2025, 13 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 13 months is above that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Sep 6, 2023
StartActual
May 21, 2024
Primary completionActual
Jul 7, 2025
CompletionActual
Jul 7, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06024408
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
May 21, 2024
Primary completion
Jul 7, 2025
Completion
Jul 7, 2025
Last update
Jul 31, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion